naltrexone has been researched along with antipyrine in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (44.44) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jolivette, LJ; Ward, KW | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Ferrari, A; Ferretti, C; Pini, LA; Sternieri, E; Trenti, T | 1 |
| Blasberg, RG; Hiraga, S; Ito, K; Patlak, CS; Pettigrew, KD; Sawada, Y | 1 |
| Blasberg, RG; Channing, M; Kawai, R; Newman, AH; Rice, KC; Sawada, Y | 1 |
| Dixon, R; Frye, RF; Matzke, GR; Rabinovitz, M; Schade, R | 1 |
| Hussar, DA | 1 |
9 other study(ies) available for naltrexone and antipyrine
| Article | Year |
|---|---|
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Topics: Algorithms; Animals; Dogs; Haplorhini; Humans; Pharmaceutical Preparations; Pharmacokinetics; Rats; Species Specificity; Tissue Distribution | 2005 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Effects of long-term treatment with naltrexone on hepatic enzyme activity.
Topics: Administration, Oral; Adult; Alkaline Phosphatase; Antipyrine; Cannabis; Female; gamma-Glutamyltransferase; Half-Life; Humans; Liver; Male; Naltrexone; Substance-Related Disorders | 1991 |
Cerebrovascular transport of [125I]quinuclidinyl benzilate, [3H]cyclofoxy, and [14C]iodoantipyrine.
Topics: Animals; Antipyrine; Biological Transport; Blood Proteins; Capillaries; Carbon Radioisotopes; Cerebrovascular Circulation; Diffusion; Erythrocytes; Indicator Dilution Techniques; Iodine Radioisotopes; Male; Models, Cardiovascular; Naltrexone; Permeability; Quinuclidines; Quinuclidinyl Benzilate; Rats; Time Factors; Tritium | 1990 |
BBB transport and rapid tissue binding of cyclofoxy: comparison of active and inactive enantiomers.
Topics: Animals; Antipyrine; Binding, Competitive; Biological Transport; Blood-Brain Barrier; Cerebrovascular Circulation; Hydrogen-Ion Concentration; Kinetics; Lipid Metabolism; Male; Naltrexone; Rats; Rats, Inbred Strains; Stereoisomerism | 1990 |
Effects of liver disease on the disposition of the opioid antagonist nalmefene.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Case-Control Studies; Female; Galactose; Glucuronates; Humans; Injections, Intravenous; Liver Diseases; Male; Matched-Pair Analysis; Middle Aged; Naltrexone; Narcotic Antagonists; Severity of Illness Index | 1997 |
New Drugs 2018, part 1.
Topics: Aminoisobutyric Acids; Antibodies, Monoclonal; Antibodies, Neutralizing; Antipyrine; Benzamides; Benzimidazoles; Broadly Neutralizing Antibodies; Carbamates; Cyclopropanes; Drug Approval; Drug Combinations; Edaravone; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Naltrexone; Natriuretic Peptides; Proline; Pyridines; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; United States; United States Food and Drug Administration | 2018 |